The latest price target for Reviva Pharmaceuticals (NASDAQ:RVPH) was reported by D. Boral Capital on June 3, 2025. The analyst firm set a price target for $3.00 expecting RVPH to rise to within 12 months (a possible 306.89% upside). 15 analyst firms have reported ratings in the last year.

The latest analyst rating for Reviva Pharmaceuticals (NASDAQ:RVPH) was provided by D. Boral Capital, and Reviva Pharmaceuticals maintained their buy rating.

The last upgrade for Reviva Pharmaceuticals Holdings Inc happened on January 10, 2025 when Maxim Group raised their price target to $7. Maxim Group previously had a hold for Reviva Pharmaceuticals Holdings Inc.

The last downgrade for Reviva Pharmaceuticals Holdings Inc happened on August 16, 2024 when Maxim Group changed their price target from N/A to N/A for Reviva Pharmaceuticals Holdings Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Reviva Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Reviva Pharmaceuticals was filed on June 3, 2025 so you should expect the next rating to be made available sometime around June 3, 2026.

While ratings are subjective and will change, the latest Reviva Pharmaceuticals (RVPH) rating was a maintained with a price target of $3.00 to $3.00. The current price Reviva Pharmaceuticals (RVPH) is trading at is $0.74, which is out of the analyst’s predicted range.